首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4951213篇
  免费   383267篇
  国内免费   15691篇
耳鼻咽喉   69273篇
儿科学   158487篇
妇产科学   130422篇
基础医学   742377篇
口腔科学   137416篇
临床医学   455378篇
内科学   903821篇
皮肤病学   117299篇
神经病学   414784篇
特种医学   193730篇
外国民族医学   968篇
外科学   741294篇
综合类   139045篇
现状与发展   24篇
一般理论   2810篇
预防医学   413863篇
眼科学   116051篇
药学   352488篇
  26篇
中国医学   13006篇
肿瘤学   247609篇
  2021年   57235篇
  2019年   59573篇
  2018年   76429篇
  2017年   58614篇
  2016年   65036篇
  2015年   77476篇
  2014年   111967篇
  2013年   177774篇
  2012年   141069篇
  2011年   149016篇
  2010年   131334篇
  2009年   131247篇
  2008年   134184篇
  2007年   144054篇
  2006年   151549篇
  2005年   145678篇
  2004年   146476篇
  2003年   136262篇
  2002年   124893篇
  2001年   197331篇
  2000年   194291篇
  1999年   174358篇
  1998年   75902篇
  1997年   70620篇
  1996年   68788篇
  1995年   64370篇
  1994年   58198篇
  1993年   54018篇
  1992年   128603篇
  1991年   123422篇
  1990年   118843篇
  1989年   115412篇
  1988年   106288篇
  1987年   104354篇
  1986年   98442篇
  1985年   95854篇
  1984年   77816篇
  1983年   68475篇
  1982年   51642篇
  1981年   47726篇
  1980年   44736篇
  1979年   67699篇
  1978年   53062篇
  1977年   46618篇
  1976年   43259篇
  1975年   44064篇
  1974年   49002篇
  1973年   46938篇
  1972年   43932篇
  1971年   40630篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area.  相似文献   
52.
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (= 768 SMV/PR,= 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity.  相似文献   
53.
54.
55.
56.
57.
58.
59.
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号